|Speaker:||Alexander D. Shenderov, Ph.D.|
|Primary Industry:||Pharma & Biotech|
|Executive Summary:||Nanolytics Inc. develops nanodroplet microfluidics solutions for drug discovery and development; clinical diagnostics; biodefense; and environmental and food monitoring markets. Our proprietary solutions allow over 100-fold savings on existing assays over traditional formats, while enabling assays not feasible with current technologies. For example, the amount of blood drawn from a finger suffices for 300 different analyses. Tests currently performed in laboratory (~1 week lead time) can be done in doctor’s office, or in the field, in minutes. This is an important capability for clinical diagnostics, biodefense, and environmental and food monitoring, which is not available today. For drug discovery, the ability to perform assays in small volumes at high throughput allows using the wealth of potential therapeutic targets coming out of Human Genome Project (well over 200,000 proteins and protein isoforms). Currently, less than 500 targets are used in drug discovery process.
Serious inquiries only, please! Our funding to date has exceeded $5M, so please don’t expect to get a major stake at Nanolytics for $100K.|